Study of VYD2311 for the Prevention of COVID-19
Public ClinicalTrials.gov record NCT07298434. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Triple-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VYD2311 for the Prevention of COVID-19 in Adults and Adolescents
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is being tested in adults and adolescents at least 12 years old. Participants in this study will be given a "study drug" that will be either VYD2311 or placebo. The study drug will be given as a shot into the muscle in the participant's upper thigh or upper arm once a month with a total of 3 shots during the study. This study will help researchers see how well VYD2311 works to prevent COVID-19 during the 90 days after the first shot. The study will also look at the safety and tolerability of VYD2311, how the study drug is processed by the body (pharmacokinetics), how the immune system reacts to the study drug (immunogenicity), and how well VYD2311 can block the virus from infecting cells (neutralization). To do these tests, your blood will be drawn at certain times during the study.
Study identification
- NCT ID
- NCT07298434
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,770 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 7, 2026
- Primary completion
- Jul 31, 2026
- Completion
- Jul 31, 2026
- Last update posted
- Jun 9, 2026
2026
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Invivyd Investigative Site | Long Beach | California | 90806 | — |
| Inviviyd Investigative Site | San Diego | California | 92103 | — |
| Invivyd Investigative Site | Orlando | Florida | 32819 | — |
| Invivyd Investigative Site | Hinesville | Georgia | 31313 | — |
| Invivyd Investigative Site | Melrose Park | Illinois | 60160 | — |
| Invivyd Investigative Site | Lenexa | Kansas | 66219 | — |
| Invivyd Investigative Site | Silver Spring | Maryland | 20904 | — |
| Invivyd Investigative Site | Burlington | Massachusetts | 01803 | — |
| Invivyd Investigative Site | Southfield | Michigan | 48034 | — |
| Invivyd Investigative Site | Maplewood | Minnesota | 55109 | — |
| Invivyd Investigative Site | Independence | Missouri | 64055 | — |
| Invivyd Investigative Site | Jersey City | New Jersey | 07306 | — |
| Invivyd Investigative Site | The Bronx | New York | 10455 | — |
| Invivyd Investigative Site | Philadelphia | Pennsylvania | 19107 | — |
| Invivyd Investigative Site | Myrtle Beach | South Carolina | 29572 | — |
| Invivyd Investigative Site | Goodlettsville | Tennessee | 37072 | — |
| Invivyd Investigative Site | Houston | Texas | 77065 | — |
| Invivyd Investigative Site | Houston-2 | Texas | 77065 | — |
| Invivyd Investigative Site | Irving | Texas | 75061 | — |
| Invivyd Investigative Site | Sugar Land | Texas | 46254 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07298434, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07298434 live on ClinicalTrials.gov.